Cargando…

Comparative evaluation of incretin‐based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure

Aims/Introduction: To compare clinical consequences of using inretin‐based medications versus conventional antidiabetic agents as add‐on to metformin in case of monotherapy failure in patients with type 2 diabetes. Materials and Methods: The medical literature including recent abstracts from inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nauck, Michael A, Vardarli, Irfan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020674/ https://www.ncbi.nlm.nih.gov/pubmed/24843405 http://dx.doi.org/10.1111/j.2040-1124.2010.00004.x

Ejemplares similares

Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments
por: Tura, Andrea, et al.
Publicado: (2022)

Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users
por: Gamble, John-Michael, et al.
Publicado: (2016)

Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
por: Mearns, Elizabeth S., et al.
Publicado: (2015)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

Incretin action on bone: An added benefit?
por: Ma, Ronald C W, et al.
Publicado: (2015)

Incretin-based therapies in 2021 – Current status and perspectives for the future
por: Rizzo, Manfredi, et al.
Publicado: (2021)

Incretin hormones and type 2 diabetes
por: Nauck, Michael A., et al.
Publicado: (2023)

Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
por: Jermendy, György, et al.
Publicado: (2008)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
por: Nauck, Michael A.
Publicado: (2013)

Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients
por: Firouzjaei, A, et al.
Publicado: (2016)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator
por: Chen, Yu-Ching, et al.
Publicado: (2015)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Incretin-based therapies
por: Stonehouse, Anthony H, et al.
Publicado: (2012)

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
por: Qian, Dan, et al.
Publicado: (2018)

Uncovering antiobesity-related hypertension targets and mechanisms of metformin, an antidiabetic medication
por: Yang, Lu, et al.
Publicado: (2021)

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
por: Nauck, M.
Publicado: (2016)

Therapy in the Early Stage: Incretins
por: Cernea, Simona, et al.
Publicado: (2011)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

Genetic Determinants Predicting Efficacy of Glucose-Lowering Drugs?: A long way to go …
por: Nauck, Michael A., et al.
Publicado: (2010)

Metformin and incretin-based therapies up-regulate central and peripheral Adenosine monophosphate-activated protein affecting appetite and metabolism
por: Nakano, Masako, et al.
Publicado: (2012)

Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
por: Moon, Jun Sung
Publicado: (2019)

Pancreatitis Associated With Incretin-Based Therapies
por: Iyer, Shridhar N., et al.
Publicado: (2013)

Incretins in the Therapy of Diabetic Kidney Disease
por: Przezak, Agnieszka, et al.
Publicado: (2021)

Socioeconomic aspects of incretin-based therapy
por: Karagiannis, Thomas, et al.
Publicado: (2023)

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
por: Meier, Juris J., et al.
Publicado: (2010)

The Impact of Incretin-Based Medications on Lipid Metabolism
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
por: Pratley, Richard E., et al.
Publicado: (2017)

Incretin Concepts
por: Bloomgarden, Zachary T.
Publicado: (2010)

Inflammation and incretins
por: Hatwal, Amitabh
Publicado: (2012)

What Is the Optimal Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients?: The Practical Evidence of Antidiabetic Monotherapy Study
por: Choi, Ji Hun, et al.
Publicado: (2011)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
por: DeCarlo, Kristen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8n274tu3kbjac29mvu1ihttfmu